Relapsed/Refractory Multiple Myeloma Clinical Trials

21 recruiting

Frequently Asked Questions

Common questions about Relapsed/Refractory Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 2

ELISA in Relapsed/Refractory MM

Relapsed/Refractory Multiple MyelomaRelapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital30 enrolled3 locationsNCT06832865
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled86 locationsNCT05160584
Recruiting
Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled108 locationsNCT07391657
Recruiting
Phase 1

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled11 locationsNCT05862012
Recruiting
Phase 2

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Multiple MyelomaRelapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.100 enrolled3 locationsNCT07284758
Recruiting
Phase 1

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma(MM)
Hadassah Medical Organization60 enrolled1 locationNCT07333430
Recruiting
Not Applicable

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma(MM)
Nanjing Legend Biotech Co.35 enrolled4 locationsNCT07100067
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd342 enrolled26 locationsNCT06049290
Recruiting
Phase 1

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 Hospital18 enrolled1 locationNCT07139509
Recruiting
Early Phase 1

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Phase 1

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.50 enrolled16 locationsNCT05722418
Recruiting
Phase 1Phase 2

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
AstraZeneca80 enrolled37 locationsNCT05850234
Recruiting
Phase 1Phase 2

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 3

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.360 enrolled12 locationsNCT06508983
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793
Recruiting
Early Phase 1

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Chunrui Li24 enrolled1 locationNCT06791681
Recruiting
Phase 2

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Biocad100 enrolled20 locationsNCT06668792
Recruiting
Not Applicable

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

Lymphoma, Non-HodgkinAcute Lymphocytic LeukemiaRelapsed/Refractory Multiple Myeloma
Shanxi Bethune Hospital45 enrolled1 locationNCT06783816